Multipark

Faculty of Medicine | Lund University

MultiPark

MOVING SCIENCE FORWARD

MultiPark is a strategic research area funded by the Swedish Government. Building on the strong tradition of cutting-edge research on Parkinson's and Alzheimer's diseases at Lund University, our vision is to create new and innovative strategies for improved and novel treatments, disease modifications and eventually cures for neurodegenerative diseases, in order to improve the quality of life for people living and ageing with these disorders.

News

Researchers have long sought treatments that can slow the progression of Parkinson's disease. Current treatments have for decades been only symptomatic in nature, supplying the neurotransmitter dopamine, which the dying nerve cells can no longer produce. Results from a recent clinical study offer hope that future therapies could take advantage of the brain's own protective mechanisms to limit neuronal cell death and restore dopamine production to natural levels.

Involuntary dyskinetic movements induced by treatment with levodopa (L-dopa) are a common problem for people with Parkinson’s disease. Now, however, researchers at Karolinska Institutet and Lund Universityseem to be close to a novel therapy to this distressing side effect. A treatment study published in the journal Brain shows that a drug that stimulates certain serotonin receptors in the brain counteracts the dyskinesia causing effects of L-dopa.

A new study from MultiPark scientists indicates that inherited viruses that are millions of years old play an important role in building up the complex networks that characterise the human brain.

In the retail business, the term G-force is routinely used to promote “hi-tech” products, whether it be racing gear, clothing or watches with uniquely durable qualities. In May of this year, a group of Parkinson’s researchers chose that same name for a global alliance with real technological prowess.

A major breakthrough in the development of stem cell-derived brain cells has put MultiPark-researchers on a firm path towards the first ever stem cell transplantations in people with Parkinson’s disease. A new study presents the next generation of transplantable dopamine neurons produced from stem cells. These cells carry the same properties as the dopamine neurons found in the human brain.

multipark logga orginal

Contact

For more information, please contact:

Jens Persson, Public Relations Officer
 +46 46 222 08 76
 jens.persson@med.lu.se 

Site overview